Skip to main content
main-content

The independent medical news service

Lung cancer

26-11-2020 | Oncology | News | Article

Oligometastatic cancer outcomes acceptable with SABR

Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.

18-11-2020 | Oncology | News | Article

Lung cancer screening adherence rates suboptimal in real-world studies

Real-world lung cancer screening rates are generally much lower than those reported in randomized controlled trials, particularly when shorter screening intervals are used, US study findings indicate.

12-11-2020 | Oncology | News | Article

Pooled analysis shows potential of radiotherapy–immunotherapy for metastatic NSCLC

Patients with metastatic non-small-cell lung cancer may benefit from the combination of radiotherapy and pembrolizumab, suggests a pooled analysis of two randomized controlled trials.

09-11-2020 | Oncology | News | Article

Multisystem irAEs signal improved ICI response in NSCLC patients

Researchers have identified an association between the development of multisystem immune-related adverse events and improved survival outcomes in immune checkpoint inhibitor-treated patients with advanced non-small-cell lung cancer.

02-11-2020 | Oncology | News | Article

‘No role’ for cetuximab–afatinib in first-line treatment of EGFR-mutated NSCLC

Treatment-naïve EGFR-mutant non-small-cell lung cancer patients are unlikely to benefit from the addition of cetuximab to afatinib, results suggest.

27-10-2020 | Oncology | News | Article

Neoadjuvant nivolumab with chemotherapy promising for stage IIIA NSCLC

The phase 2 NADIM study points to the potential of neoadjuvant treatment with nivolumab plus platinum-based chemotherapy in treatment-naïve patients with resectable, stage IIIA non-small-cell lung cancer.

26-10-2020 | Oncology | News | Article

Optimal extensive-stage SCLC first-line regimen identified

Combining a PD-L1 inhibitor with an etoposide–platinum chemotherapy regimen may be the optimal first-line treatment for patients with extensive-stage small-cell lung cancer, network meta-analysis findings suggest.

23-10-2020 | Oncology | News | Article

FDA recommends nivolumab–ipilimumab for inoperable mesothelioma

Read more on this announcement here

20-10-2020 | Oncology | News | Article

Switch maintenance therapy not suitable for older NSCLC patients

Older patients with non-small-cell lung cancer who have not progressed on platinum-based doublet therapy do not gain an overall survival advantage if treated with switch maintenance therapy rather than observation, study findings show.

16-10-2020 | Oncology | News | Article

EMA supports first-line ipilimumab plus nivolumab for NSCLC

Click through to read more

09-10-2020 | Oncology | News | Article

​​​​​​​CheckMate 9LA PROs add support for first-line nivolumab–ipilimumab for advanced NSCLC

CheckMate 9LA trial findings indicate that a front-line nivolumab plus ipilimumab-based regimen slows the decline in health-related quality of life for advanced non-small-cell lung cancer patients compared with chemotherapy alone.

07-10-2020 | Oncology | News | Article

Amivantamab plus lazertinib show promise for advanced EGFR-mutated NSCLC

CHRYSALIS trial findings suggest that the bispecific monoclonal antibody amivantamab could be combined with the third-generation EGFR–tyrosine kinase inhibitor lazertinib for the treatment of patients with metastatic or unresectable non-small-cell lung cancer with an EGFR exon 19 deletion or L858R mutation.

05-10-2020 | Oncology | News | Article

KEYNOTE-024: ‘Meaningful’ OS improvement with pembrolizumab maintained at 5 years

Treatment with pembrolizumab has led to a near doubling of the 5-year overall survival rate relative to chemotherapy among previously untreated patients with PD-L1-high, metastatic non-small-cell lung cancer, report the KEYNOTE-024 investigators.

01-10-2020 | Oncology | News | Article

Neoadjuvant immunotherapy explored in resectable NSCLC

Two phase 2 studies presented at the ESMO Virtual Congress 2020 have highlighted the risks and benefits of neoadjuvant immunotherapy in patients with resectable non-small-cell lung cancer.

29-09-2020 | Oncology | News | Article

Lorlatinib shows substantial benefits over crizotinib for ALK-positive NSCLC

First-line treatment with lorlatinib significantly improves progression-free survival, relative to crizotinib, in patients with advanced ALK-positive, non-small-cell lung cancer, results of the phase 3 CROWN study show.

28-09-2020 | Oncology | News | Article

ACTIVE support for adding apatinib to gefitinib for EGFR-mutated NSCLC

Chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer and EGFR-activating mutations derive prolonged progression-free survival from the addition of apatinib to gefitinib, phase 3 ACTIVE data show.

25-09-2020 | Oncology | News | Article

Long-term ES-SCLC outcomes on durvalumab–chemotherapy predicted by PFS duration

A progression-free survival of at least 12 months is a strong indicator of good survival outcomes at 2 years in patients with extensive-stage small-cell lung cancer taking durvalumab alongside first-line platinum–etoposide, even in those with poor prognostic factors, analysis of CASPIAN data shows.

23-09-2020 | Oncology | News | Article

EMPOWER-Lung 1 shows cemiplimab efficacy for PD-L1-high advanced NSCLC

Cemiplimab monotherapy offers a significant overall survival benefit compared with platinum-doublet chemotherapy for advanced non-small-cell lung cancer patients with a PD-L1 tumor cell expression of 50% or above, indicate initial EMPOWER-Lung 1 trial findings.

22-09-2020 | Oncology | News | Article

NSCLC CNS recurrence significantly reduced with adjuvant osimertinib

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

21-09-2020 | Oncology | News | Article

Postoperative RT ‘not recommended’ for resected advanced NSCLC

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

Image Credits